Loading…
Loading…
SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- #biologics--CSQ Bio® today announced the introduction of CSQ Bio® – Surgical, its surgical-focused business, and unveiled INNESTO Rx™, a CSQ Bio®-branded surgical collagen powder. National commercial sales of INNESTO Rx™ are scheduled to begin January 4, 2027. The underlying collagen product is FDA 510(k)-cleared. CSQ Bio® – Surgical will focus on national commercialization of surgical products, working with manufacturers and healthcare organizations on product introduct.
METRO CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- Calamos Investments®* has announced monthly distributions and sources of distributions paid in October 2026 to shareholders of its seven closed-end funds (the Funds) pursuant to the Funds' respective distribution plans.
Calamos Strategic Total Return Fund is a $5.2B CEF focused on equities, convertibles, and high-yield credit, employing significant leverage. CSQ has delivered strong historical NAV returns and supports its sizable 7.8% dividend primarily through capital appreciation rather than income. Despite robust performance, I rate CSQ a Hold due to its current 7.8% discount not offering a sufficient margin of safety given 30% leverage and high fees.
Calamos Strategic Total Return Fund is rated Buy, leveraging diversified equities and fixed income with a strong tilt toward information technology and financials. CSQ's overweight in AI-driven mega-cap tech and financials positions the fund for outperformance amid a risk-on market and ongoing AI capital investment cycles. Convertible bonds and preferred stock holdings add income durability, while 30% leverage aims to amplify returns despite macroeconomic volatility.
METRO CHICAGO, Ill., Sept. 1, 2026 /PRNewswire/ -- Calamos Investments®* has announced monthly distributions and sources of distributions paid in September 2026 to shareholders of its seven closed-end funds (the Funds) pursuant to the Funds' respective distribution plans.
METRO CHICAGO, Ill., Aug. 26, 2026 /PRNewswire/ -- The Boards of Trustees of six of Calamos Investments' closed-end funds (the Funds) today announced the issuance of additional series of mandatory redeemable preferred (MRP) shares totaling $248.25 million.
METRO CHICAGO, Ill., Aug. 3, 2026 /PRNewswire/ -- Calamos Investments®* has announced monthly distributions and sources of distributions paid in August 2026 to shareholders of its seven closed-end funds (the Funds) pursuant to the Funds' respective distribution plans.
Calamos Strategic Total Return Fund remains a buy, trading at a 9.13% discount to NAV and offering a 7.8% dividend yield. CSQ's portfolio blends large-cap tech equities and income securities, but relies heavily on net realized gains to support distributions. Leverage at 27.78% and interest rate sensitivity present risks, especially if rates rise or tech sentiment shifts negatively.